Shanghai Medicilon Inc (688202) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Medicilon Inc (688202) has a cash flow conversion efficiency ratio of -0.010x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-17.10 Million ≈ $-2.50 Million USD) by net assets (CN¥1.74 Billion ≈ $254.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Shanghai Medicilon Inc to measure how much of total assets are equity-financed.
Shanghai Medicilon Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Shanghai Medicilon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Shanghai Medicilon Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Shanghai Medicilon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Medicilon Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Expressway Co. Ltd
F:ZHJ
|
0.012x |
|
Allied Gold Corporation
NYSE:AAUC
|
0.432x |
|
Oil Refineries Ltd.
TA:ORL
|
0.108x |
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
-0.036x |
|
Concentrix Corporation
NASDAQ:CNXC
|
-0.030x |
|
TECNOGLASS INC. DL-0001
F:7FH
|
0.043x |
|
Bank of Chongqing Co Ltd
F:CQN
|
-0.075x |
|
Nations Technologies Inc
SHE:300077
|
-0.129x |
Annual Cash Flow Conversion Efficiency for Shanghai Medicilon Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Medicilon Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 688202 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.93 Billion ≈ $283.04 Million |
CN¥105.17 Million ≈ $15.39 Million |
0.054x | +611.58% |
| 2024-12-31 | CN¥2.14 Billion ≈ $313.17 Million |
CN¥-22.75 Million ≈ $-3.33 Million |
-0.011x | -180.10% |
| 2023-12-31 | CN¥2.51 Billion ≈ $367.41 Million |
CN¥33.32 Million ≈ $4.88 Million |
0.013x | +199.71% |
| 2022-12-31 | CN¥1.60 Billion ≈ $234.54 Million |
CN¥-21.33 Million ≈ $-3.12 Million |
-0.013x | -103.90% |
| 2021-12-31 | CN¥1.33 Billion ≈ $194.26 Million |
CN¥452.94 Million ≈ $66.28 Million |
0.341x | +86.49% |
| 2020-12-31 | CN¥1.14 Billion ≈ $166.18 Million |
CN¥207.77 Million ≈ $30.40 Million |
0.183x | +214.00% |
| 2019-12-31 | CN¥1.00 Billion ≈ $146.42 Million |
CN¥58.30 Million ≈ $8.53 Million |
0.058x | -71.49% |
| 2018-12-31 | CN¥347.89 Million ≈ $50.91 Million |
CN¥71.11 Million ≈ $10.41 Million |
0.204x | -21.38% |
| 2017-12-31 | CN¥287.32 Million ≈ $42.04 Million |
CN¥74.70 Million ≈ $10.93 Million |
0.260x | +87.44% |
| 2016-12-31 | CN¥246.09 Million ≈ $36.01 Million |
CN¥34.13 Million ≈ $4.99 Million |
0.139x | -- |
About Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development; custom and zoom in synthesis; structural, in … Read more